**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 73526

**Manuscript Type:** LETTER TO THE EDITOR

**Advances and effectiveness of the immunotherapy after liver transplantation**

Vulasala SSR *et al*. Immunotherapy after liver transplantation

Sai Swarupa R Vulasala, Nirmal K Onteddu, Sindhu P Kumar, Chandana Lall, Priya Bhosale, Mayur K Virarkar

**Sai Swarupa R Vulasala, Sindhu P Kumar, Chandana Lall, Mayur K Virarkar,** Department of Radiology, University of Florida College of Medicine, Jacksonville, FL 32209, United States

**Nirmal K Onteddu,** Department of Internal Medicine, Flowers Hospital, Dothan, AL 36305, United States

**Priya Bhosale,** Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

**Author contributions:** Vulasala SSR, Onteddu NK, Kumar SP, Lall C, Bhosale P, and Virarkar MK have equal contributions to this article.

**Corresponding author: Sai Swarupa R Vulasala, MBBS, Research Assistant,** Department of Radiology, University of Florida College of Medicine, 655 West 8th Street, C90, 2nd Floor, Clinical Center, Jacksonville, FL 32209, United States. vulasalaswarupa@gmail.com

**Received:** November 23, 2021

**Revised:** January 15, 2022

**Accepted:** June 13, 2022

**Published online:** June 27, 2022

**Abstract**

Transplant recipients usually have increased chances of graft rejection and graft *vs* host disease, requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients. The authors reported the graft rejection rates and the factors contributing to the rejection in the liver transplant recipients.

**Key Words:** Immunotherapy; Hepatocellular carcinoma; Immune checkpoint inhibitors; Liver transplantation; Solid organ transplant; Graft rejection

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Vulasala SSR, Onteddu NK, Kumar SP, Lall C, Bhosale P, Virarkar MK. Advances and effectiveness of the immunotherapy after liver transplantation. *World J Gastrointest Surg* 2022; 14(6): 629-631

**URL:** https://www.wjgnet.com/1948-9366/full/v14/i6/629.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v14.i6.629

**Core Tip:** There is an increased risk of cancer among transplant recipients receiving chronic immunosuppression. Immunotherapy has a beneficiary effect over immunosuppressors in reducing the overall cancer risk. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients.

**TO THE EDITOR**

Au *et al*[1] studied the consequences of immunotherapy in patients who underwent liver transplantation (LT) for hepatocellular carcinoma (HCC). We are writing to thank the authors after reading their article conscientiously. Many trials were conducted in the literature studying the efficacy of immunotherapy. However, they excluded organ transplant recipients due to the higher risk of fatal graft rejection.

Transplant recipients usually have increased chances of graft rejection and graft *vs* host disease (GVHD), requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. These malignancies constitute the second most common cause of death in organ transplant recipients[2]. Immunotherapy is a breakthrough in managing transplant recipients and acts through interruption of the cancer-immunity cycle. Immune checkpoints, cytotoxic T-lymphocyte antigen 4 (CTLA-4), and programmed cell death 1 (PD-1) are physiologically responsible for preventing effector T cell overactivation.

Immunotherapy includes antibodies against CTLA-4 and PD-1, thereby upregulating the T-cell immune response to the cancer antigen[3]. Although the host immunity against tumor antigens is restored, on the other hand, T-cell stimulation is one of the significant components of graft rejection. The overall rejection rates following immunotherapy are 29%-54% and 25%, respectively, in patients who underwent solid organ transplantation and LT[4-6]. Kidney (40%) is associated with higher rates of graft rejection than liver (35%) and heart (20%)[3]. Au *et al*[1] studied that the graft rejection rates were seen in 32% of patients who specifically underwent an LT. The rejection rates among individuals who received immunotherapy within 2.9 years of transplant were increased compared to 5.3 years of transplant. They also noticed a higher mortality rate of 56% among graft rejected patients.

Compared with CTLA-4 inhibitors, PD-1 inhibitors are associated with higher rates of graft rejection and graft loss in LT recipients[7,8]. Kittai *et al*[9] reported graft rejection in 4 of 8 patients treated with anti-PD-1, whereas no rejections were detected in patients receiving anti-CTLA-4 therapy. Programmed death-ligand 1 (PD-L1) expression on the graft lymphocytes aids as a marker of rejection after immunotherapy[2]. Tacrolimus-based or combination agents (corticosteroids, antimetabolites, calcineurin inhibitors, and mechanistic target of rapamycin inhibitors) immunosuppression is shown to reduce graft rejection and improve the response to immunotherapy[2]. A 10%-20% of post-transplant patients encounter recurrence of HCC[10]. In such cases, immunotherapy is effective only in 11% of patients.

A higher dose of immunotherapy medication, a shorter interval between LT and immunotherapy initiation, expression of PD-L1 on the graft lymphocytes, and a previous GVHD history are positively related with the risk of and response to graft rejection[4]. Studies on patient characteristics such as gender, age, pathological type of primary tumor, donor type, type, and duration of ischemia during LT and post-operative hepatitis virus status of the patient are necessary to learn the factors associated with favorable outcomes after immunotherapy. Proper patient selection is quintessential to preventing lethal graft rejection. Hence, a close collaboration among oncologists and transplant specialists is encouraged when handling patients who require immunotherapy. However, prospective studies focusing on: (1) Although the PD-1 pathway is dominant in establishing immune tolerance, whether anti-PD-1 and anti-CTLA-4 antibodies are associated with graft rejection[9]; (2) The treatment of immunotherapy related graft rejection; and (3) Its efficacy is there any difference in treatment modality between immunotherapy related graft rejection and isolated graft rejection, are required beforehand to recommend immune checkpoint inhibitors in transplant recipients.

**REFERENCES**

1 **Au KP**, Chok KSH. Immunotherapy after liver transplantation: Where are we now? *World J Gastrointest Surg* 2021; **13**: 1267-1278 [PMID: 34754394 DOI: 10.4240/wjgs.v13.i10.1267]

2 **Kumar V**, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. *Oncologist* 2020; **25**: 505-514 [PMID: 32043699 DOI: 10.1634/theoncologist.2019-0659]

3 **Fisher J**, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. *J Am Acad Dermatol* 2020; **82**: 1490-1500 [PMID: 31302190 DOI: 10.1016/j.jaad.2019.07.005]

4 **Hu B**, Yang XB, Sang XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review. *Med Oncol* 2019; **36**: 94 [PMID: 31605245 DOI: 10.1007/s12032-019-1316-7]

5 **Ijaz A**, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. *Biol Blood Marrow Transplant* 2019; **25**: 94-99 [PMID: 30195074 DOI: 10.1016/j.bbmt.2018.08.028]

6 **Gassmann D**, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, Mangana J, Müllhaupt B, Jenni F, Misselwitz B. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. *Transplant Direct* 2018; **4**: e376 [PMID: 30255136 DOI: 10.1097/TXD.0000000000000814]

7 **Tio M**, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. *Eur J Cancer* 2018; **104**: 137-144 [PMID: 30347289 DOI: 10.1016/j.ejca.2018.09.017]

8 **Wanchoo R**, Riella LV, Uppal NN, Lopez CA, Nair V, Devoe C, Jhaveri KD. Immune checkpoint inhibitors in the cancer patient with an organ transplant. *J Onco-Nephrol* 2017; **1**: 42-48 [DOI: 10.5301/jo-n.5000006]

9 **Kittai AS**, Oldham H, Cetnar J, Taylor M. Immune Checkpoint Inhibitors in Organ Transplant Patients. *J Immunother* 2017; **40**: 277-281 [PMID: 28719552 DOI: 10.1097/CJI.0000000000000180]

10 **Johnston MP**, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. *World J Gastroenterol* 2019; **25**: 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** November 23, 2021

**First decision:** January 12, 2022

**Article in press:** June 13, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Chen YH, China; Koc ÖM, Belgium **A-Editor:** Garg P, India **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**